Table 1. General characteristics of included cost-effectiveness analyses and model-based economic evaluations.
| Reference | Country | Patients | Sample size (IG,CG) | Mean/median age (IG,CG) | Time horizon | Model type | Data source | Perspective | Year of pricing |
|---|---|---|---|---|---|---|---|---|---|
| CEA | |||||||||
| Andronis et al. [57] | UK | mCRPC | 707 (350,357) | 69a | Lifetime | − | RCT | PAY | 2012 |
| Bloomfield et al. [58] | CAN | CRCP | 114 | n.a. | Lifetime | − | RCT | PAY | 1996 |
| James et al. [59] | UK | mCRPC | 707 (350,357) | 69a | Lifetime | − | RCT | SOC | 2012 |
| Reed et al. [60] | AT, AU, BE, CAN, FR, DE, IT, NZ, SE, CH, UK, US | mCRPC | 360 (181,179) | 73 | 15 months | − | RCT | PAY | 2000 |
| MEE | |||||||||
| Carter et al. [61] | FR, DE, PT, NL | mCRPC | − | 72 | n.a. | Decision model | Saad et al. [93] | PAY | 2007 |
| Collins et al. [56] | UK | mCRPC | − | − | 180 months | Markov model | Tannok et al. [19] | PAY | 2003 |
| Gong & Hay [62] | US | mCRPC | − | 70 | Lifetime | Markov model | De Bono et al. [14], Kantoff et al. [16] | SOC | 2013 |
| Holko & Kawalec [63] | US | CRPC | − | − | Lifetime | Markov model | Kantoff et al. [16] | PAY | 2012 |
| Konski [64] | US | mCRPC with bone metastases | − | − | 24 months | Markov model | Various studies [94–100] | PAY | 2004b |
| Massoudi et al. [65] | US | mCRPC | − | − | 12 months | Statistical analysis | Beer et al. [13], Rathkopf et al. [101] | PAY | 2015 |
| Peters et al. [55] | NL | mCRPC | − | − | Lifetime | Markov model | Various studies [15, 17, 18, 102] | SOC | 2017 |
| Pilon et al. [66] | US | mCRPC | − | − | n.a. | Statistical analysis | Various studies [13, 25, 101, 103] | PAY | 2015 |
| Pollard et al. [67] | US | mCRPC | − | − | Lifetime | Decision-tree model | Various studies [14–19, 104] | PAY | 2017b |
| Snedecor et al. [68] | US | mCRPC with bone metastases | − | − | 27 months | Markov model | Fizazi et al. [102] | PAY | 2010 |
| Stopeck et al. [69] | US | mCRPC with bone metastases | − | − | Lifetime | Markov model | Fizazi et al. [102], Stopeck et al. [105], Henry et al. [106] | PAY | 2011 |
| Wilson et al. [70] | US | DX-refractory mCRPC | − | − | 18 months | Decision-tree model | De Bono et al. [14], De Bono et al. [15], Scher et al. [18] | PAY | 2012 |
| Xie et al. [71] | US | mCRPC with bone metastases | − | − | 12 months, 36 months | Markov model | Fizazi et al. [102] | PAY | 2010 |
| Zhong et al. [72] | US | DX-refractory mCRPC | − | − | 18 months | Decision-tree model | De Bono et al. [14], De Bono et al. [15] | SOC | 2010 |
| Zubek & Konski [73] | US | CRPC | − | − | 120 months | Markov model | Cordon-Cardo et al. [107] | PAY | 2006 |
AT: Austria, AU: Australia, BE: Belgium, CAN: Canada, CEA: cost-effectiveness analysis, CG: control group, CH: Switzerland, CRPC: castration-resistant prostate cancer, DE: Germany, DX: docetaxel, FR: France, IG: intervention group, IT: Italy, mCRPC: metastatic castration-resistant prostate cancer, MEE: model-based economic evaluation, n.a.: not available, NL: the Netherlands, NZ: New Zealand, PAY: costs are reported from the perspective of a third-party payer, PT: Portugal, SE: Sweden, SOC: costs are reported from the perspective of the society, UK: United Kingdom, US: United States.
a based on a larger data set
b The submission year/study year was assumed as base year.